Artiva Biotherapeutics, Inc.
ARTV
$1.98
-$0.07-3.42%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -45.46% | -34.15% | -254.91% | -58.13% | 16.47% |
| Total Depreciation and Amortization | 6.98% | 3.37% | 12.77% | 12.08% | 1.56% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.76% | -37.11% | 83.58% | 45.74% | -28.71% |
| Change in Net Operating Assets | 50.70% | 71.39% | 112.65% | 99.80% | -4,812.50% |
| Cash from Operations | -31.52% | -37.24% | -8.03% | -16.33% | -5.92% |
| Capital Expenditure | -2,738.89% | 89.94% | 46.37% | 20.14% | 99.03% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 6.96% | 55.61% | -41,470.70% | 108.90% | -- |
| Cash from Investing | 1.93% | 63.79% | -26,396.55% | 106.44% | 625.35% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | 120.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -102.08% | -111.11% | -- | -- |
| Cash from Financing | -- | -103.12% | 599.38% | -16,260.00% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -81.58% | -26.37% | 77.47% | 57.34% | 67.09% |